- Jim Spencer promoted to president of Kinney Drugs stores
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- CVS Caremark's Merlo attends reception to accept March of Dimes Citizen of the Year award
- Senate passes Drug Quality and Security Act
- Countdown to McKesson ideaShare 2013: MiS to compile best thinking, new ideas for independent pharmacy
NEW YORK — Bristol-Myers Squibb announced changes to its senior management team, including the appointment of its U.S. pharmaceuticals president.
The drug maker said SVP oncology and immunology global commercialization Giovanni Caforio has been promoted to president of U.S. pharmaceuticals. Additionally, Bristol named Charles Bancroft and Béatrice Cazala as EVPs. Bancroft will add to his role of CFO operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim. Meanwhile, Cazala will add responsibility for global policy to her role leading global commercialization, Europe and emerging markets.
In related news, Anthony Hooper, SVP commercial operations and president of U.S., Japan and intercontinental, has decided to leave the company. He has joined Amgen as EVP global commercial operations.
All of the executives will report to Bristol CEO Lamberto Andreotti.
“A focus on developing talent at all levels is a key element of our Bristol-Myers Squibb culture,” Andreotti said. “I am excited to expand the roles of Giovanni, Charlie and Béatrice, and look forward to working with these three senior leaders and the rest of my management team to continue to successfully execute our BioPharma strategy.”